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epidermolysis Bullosa:  
Prospects for Cell-Based Therapies
Jouni Uitto1
Heritable forms of epidermolysis bullosa (eB) are characterized by chronic, lifelong 
blistering and erosions due to mutations in 10 distinct genes expressed at the cuta-
neous basement membrane zone. No specific treatment for this group of intract able 
diseases is currently available. recent progress in molecular therapies has indicated 
that cell-based approaches may potentially offer amelioration—and perhaps even 
cure—for afflicted individuals. In this issue, Wong et al. (2008) demonstrate the 
feasibility of direct intradermal injection of allo geneic fibroblasts to the lesional skin 
of patients with recessive dystrophic eB, with improvement in skin fragility.
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Epidermolysis bullosa (EB) is a clinically 
and genetically heterogeneous group of 
diseases presenting with skin fragility as 
the unifying diagnostic hallmark (Fine 
et al., 2008). Histopathology of the cuta-
neous blisters reveals separation of the 
epidermis from the underlying dermis 
at the level of the cutaneous basement 
membrane zone. Tremendous progress 
in molecular genetics of this group of 
disorders over the past two decades has 
revealed that the blistering tendency is 
due to mutations in 10 distinct genes 
expressed at the dermal–epidermal junc-
tion. The precise level of the expression 
of the mutated genes within the cutane-
ous basement membrane zone, the types 
and combinations of the mutations, and 
their consequences at mRNA and protein 
levels, when superimposed on the indi-
vidual’s genetic background and exposure 
to environmental trauma, all explain the 
spectrum of severity in affected individuals 
and form the basis of a molecular-based 
classification (Uitto and Richard, 2005).
Among the most severe forms of EB 
are the dystrophic subtypes, particularly 
the recessive Hallopeau–Siemens vari-
ant, (HS-RDEB). The dystrophic forms of 
EB are due to mutations in the type VII 
collagen gene, COL7A1, and HS-RDEB 
is frequently caused by premature ter-
mination codon-causing mutations that 
result in functional null alleles (Varki et 
al., 2007). As a result, blistering and ero-
sions develop upon exposure to relative-
ly minor trauma, leading to subsequent 
healing with extensive fibrosis. No spe-
cific treatment, short of protection from 
trauma, is currently available for patients 
with any form of EB.
The prospects of gene therapy for EB 
have been contemplated over the years, 
and, in fact, this disorder is an excellent 
candidate disease for molecular therapy 
approaches for several reasons (Uitto 
and Pulkkinen, 2000). First, skin is read-
ily accessible for delivery of the trans-
gene, either in the form of expression 
plasmids or packaged in cells delivered 
directly to the skin. The consequences 
of the gene delivery can be observed 
visually, and potential amelioration of 
the skin fragility can be easily measured 
by mechanical means. Furthermore, the 
treated areas of skin can be removed 
if evidence of adverse effects, such as 
cancer development, is noted. A num-
ber of preclinical model systems—such 
as transplantation of EB patients’ skin 
onto immunocompromised mice as a 
xenograft or injection of genetically cor-
rected cells, such as fibroblasts, to RDEB 
mice—have indicated the feasibility of 
gene therapy approaches for EB (Ortiz-
Urda et al., 2003; Goto et al., 2006; 
Woodley et al., 2007; Fritsch et al., 
2008). As a direct clinical application, 
correction of skin fragility in a patient 
with junctional EB (JEB) was recently 
demonstrated (Mavilio et al., 2006). In 
this case, epidermal stem cells from the 
skin of a patient with mutations in the 
LAMB3 gene encoding the β3 subunit 
of laminin 332 were isolated and then 
transduced in culture with a retroviral 
LAMB3 expression vector. The cells were 
then grown into epidermal sheets that 
were grafted onto surgically prepared 
areas of the patient’s skin. Follow-up for 
more than 1 year has demonstrated sus-
tained synthesis and proper assembly of 
laminin 332 in the grafted area, togeth-
er with the development of a firmly 
adherent epidermis. There has been no 
evidence of blistering, inflammation, or 
immune response in the corrected area. 
These data suggested, therefore, that ex 
vivo gene therapy may be feasible for 
JEB and that this approach can lead to 
fully functional correction of the disease 
in the skin. A general concern associated 
with the use of retroviral vectors, howev-
er, is the potential for insertional carcino-
genesis due to random integration of the 
transgene to the genome (Featherstone 
and Uitto, 2007). Furthermore, only rel-
atively small areas can be treated at any 
given time, and the procedure involves 
considerable invasive preparation of the 
recipient skin for grafting. For these rea-
sons, complementary approaches uti-
lizing protein- and cell-based therapies 
have recently been contemplated.
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In this issue, Wong et al. (2008) report 
on the potential of fibroblast cell therapy 
for RDEB utilizing skin fibroblasts, either 
allogeneic (cultured from patients’ 
parents or unrelated individuals) or 
autologous (cultured from the patients 
themselves). Specifically, the investiga-
tors assessed the clinical benefits that 
may accrue from a single intradermal 
injection of these cells in five subjects 
with RDEB. Three of the subjects had 
the most severe form of HS-RDEB, and 
two had a milder phenotype. Baseline 
immunofluorescence microscopy dem-
onstrated low, barely detectable levels 
of expression of type VII collagen in two 
of the subjects, whereas three of the 
patients clearly exhibited the presence 
of type VII collagen, albeit at reduced 
levels. Transmission electron microscopy 
showed a reduced number of anchoring 
fibrils, with three patients with the most 
severe form of disease showing very 
sparse, thin, and rudimentary fibrils. Skin 
biopsies at 2 weeks after the fibroblast 
injections demonstrated up to twofold 
increases in type VII collagen immuno-
staining at the sites injected either with 
parental fibroblasts or with fibroblasts 
from unrelated donors. In contrast, there 
was no increase in type VII collagen 
immunoreactivity in the biopsies taken 
from the sites of autologous fibroblast 
injections. Repeat biopsies at 3 months 
indicated a sustained increase in type VII 
collagen in three of the five individuals.
It is of interest that this increase was 
noted in the individuals who had a 
higher baseline expression of type VII 
collagen. Increased type VII collagen 
expression was accompanied by an 
increase in the number of rudimentary 
anchoring fibrils at the allogeneic fibro-
blast–injected sites. These immuno-
histochemical and ultra structural 
changes were accompanied by objec-
tive improvement in the strength of 
adhesion between the epidermis and 
the underlying dermis at the injected 
sites. Thus, these findings suggest that 
injecting allogeneic fibroblasts into 
RDEB patients’ skin can be beneficial.
Somewhat puzzling were the ini-
tial observations that the allogeneic 
fibroblasts were not detectable in the 
skin after 2 weeks of intradermal injec-
tion; this appeared not to be associated 
with any robust inflammatory reaction. 
There was, however, an early and tran-
sient increase in the number of lympho-
cytes, increased labeling of CD11c as a 
marker of dermal dendritic cells, and a 
minor increase in dermal macrophages 
detected by CD68 staining. These 
increases returned to normal levels at 
3 months. Careful molecular analysis 
of type VII collagen gene expression at 
the mRNA level, coupled with cytokine 
expression profiling by RT-PCR, allowed 
the investigators to postulate that the 
allogeneic fibroblasts exert a paracrine 
effect on the subjects’ own keratino-
cytes, resulting in increased synthesis 
and secretion of mutant type VII colla-
gen. This postulate has implications for 
the clinical applicability of the type of 
cell therapy tested here. First, it appears 
that only patients who demonstrate a 
certain degree of baseline expression of 
type VII collagen, even mutated, would 
benefit from allogeneic fibroblast injec-
tion. In other words, patients with the 
most severe forms of HS-RDEB, dem-
onstrating complete absence of type VII 
collagen, might not benefit from fibro-
blast injection. Second, the newly syn-
thesized type VII collagen continues to 
be mutated and results in the synthesis 
of morpho logically abnormal anchoring 
fibrils, as demonstrated in this study, and 
the treatment may thus ameliorate, but 
not completely cure, the disease. Thus, 
allo geneic fibroblast injection therapy 
may be applicable only to a select sub-
population of patients with RDEB.
The improvement in RDEB patients 
by the allogeneic fibroblasts, which by 
themselves seem to be relatively short-
lived at the site of injection, is apparent-
ly predicated on the relatively long half-
life of type VII collagen molecules. The 
same approach may not be applicable 
to other forms of EB if the mutated pro-
teins are short-lived. Nevertheless, this 
study illustrates the proof of principle 
that injection of allogeneic fibroblasts 
intradermally into patients has clini-
cal merit and attests to the therapeutic 
potential of cell therapies in human sub-
jects with RDEB (Chen and Woodley, 
2006; Wong et al., 2007.
Parallel developments of cell-based 
therapies for RDEB and other cutaneous 
diseases involve various stem cell pop-
ulations, such as those derived from 
bone marrow. In fact, several studies 
presented at the recent International 
Investigative Dermatology 2008 meet-
ing in Kyoto, Japan, demonstrated the 
potential of bone marrow stem cells for 
the treatment of EB utilizing preclinical 
mouse model systems. Moreover, the 
first human clinical trial using bone mar-
row transfer of a subpopulation of stem 
cells was recently initiated, with prom-
ising early evidence of regeneration of 
type VII collagen and anchoring fibrils in 
a 1-year-old patient with HS-RDEB who 
was born entirely devoid of this protein 
(Tolar et al., submitted). Collectively, 
these studies, including those report-
ed by Wong et al. (2008) in this issue, 
demonstrate the potential of cell-based 
approaches in the repertoire of molecu-
lar therapies being developed toward 
treatment of EB, a currently intractable 
group of heritable skin diseases.
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with infections of mucosal epithelia 
and can be grouped into “low-risk” 
and “high-risk” types, depending on 
the relative propensity of the neoplasms 
that these viruses cause to undergo 
malignant progression. Low-risk HPV 
infections cause mostly benign genital 
warts (condyloma acuminata), whereas 
high-risk HPV infections can give rise 
to potentially premalignant squamous 
intraepithelial neoplasias. Although 
progression of such lesions is generally 
a slow and infrequent event, >99% of 
human cervical carcinomas are caused 
by high-risk HPV infections. In addition, 
a significant percentage of other ano-
genital tract cancers, as well as approxi-
mately 20% of human oral carcinomas, 
are associated with high-risk HPV infec-
tions. The recently introduced prophy-
lactic HPV vaccine Gardasil is used for 
protection from new infections with the 
two most common high-risk (HPV16 
and HPV18) and low-risk (HPV6 and 
HPV11) HPV types. Given the relative 
abundance of specific HPV types, these 
vaccines have the potential to prevent 
up to 70% of cervical cancers, as well 
as a similar percentage of genital warts.
High-risk α-HPVs also have a much 
higher transforming potential than low-
risk HPVs in vitro. These viruses express 
three proteins—E5, E6, and E7—that 
have transforming activities in cell- 
and or animal-based model systems. 
Of these, only E6 and E7 are regularly 
expressed in cervical cancers, and their 
persistent expression is necessary for 
the maintenance of the transformed 
phenotype.
How may β-genus HPVs contribute to 
nonmelanoma skin cancer development?
β-HPVs comprise a similarly large 
group of HPVs. The most extensively 
studied are HPV5 and HPV8. These 
are associated with EV, a rare skin 
disease that can eventually progress 
to squamous cell carcinoma, particu-
larly in sun-exposed areas of the body. 
Infection with HPV5 or HPV8 is not 
sufficient for EV development, and indi-
viduals are genetically predisposed to 
developing this condition. It is an auto-
somal recessive, genetically heteroge-
neous disease, and loci on the X chro-
mosome—17q25 (EV1) and 2p21-p24 
(EV2)—have been implicated. Two 
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The Human Papillomavirus Type 8 e2 
Gene encodes a Transforming Activity 
Sufficient for Skin Tumor formation 
in Transgenic Mice
Margaret McLaughlin-Drubin1 and Karl Münger1
Infections with β-genus human papillomaviruses (HPVs) have been associated 
with nonmelanoma skin cancers, particularly in immunocompromised patients 
and individuals with a rare genetic disease, epidermodysplasia verruciformis 
(eV). Using a transgenic mouse model, Herbert Pfister’s group determined that 
expression of the HPV8 e2 gene results in skin cancer development and that this 
process is greatly accelerated by UV irradiation (Pfefferle et al., 2008, this issue).
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HPVs encompass more than 100 geno-
types. They consist of small 8,000-bp, 
double-strand circular DNA genomes 
packaged into non-enveloped, icosahe-
dral, ~55-nm particles. The nonstructural 
early (E) genes encode proteins that are 
necessary for viral replication, whereas 
the late (L) genes, L1 and L2, encode 
the major and minor capsid proteins, 
respectively. The viral life cycle is tightly 
coupled to the differentiation process of 
the infected squamous epithelium; the 
initial infection targets the basal epithe-
lial cells, which make up the major layer 
in the skin that actively proliferates. 
High-level viral genome replication, 
expression of late genes, and produc-
tion of viral progeny, however, are 
restricted to the suprabasal, terminally 
differentiated layers of the skin. Hence, 
HPVs encode activities to reprogram 
the infected cell by uncoupling growth 
arrest and differentiation programs, and 
this is clinically manifested by the for-
mation of generally benign epithelial 
hyperplasias, or warts.
HPVs are classified into several phylo-
genetic groups. Of these, the α-genus 
HPVs have been studied most exten-
sively. α-genus HPVs are associated 
